2101 COTTONTAIL LANE, SOMERSET, NJ
Proof 2 12 - Aug - 26 ABSTAIN AGAINST FOR ABSTAIN AGAINST FOR Res. 5 Res. 1 Res. 6 Res. 2 Res. 7 Res. 3 Res. 8 Res. 4
Reports Second Quarter 2026 Results and Recent Highlights
Material disclosure
Announces Preliminary Sales for CARVYKTI® for the Quarter Ended June 30, 2026
Announces Pricing of Public Offering
EHA 2026 Recap June 2026 © 2026 . All rights reserved.
First-in-human trial of LB2501, an in vivo CD19/CD20 dual targeting CAR-T therapy, in relapsed/refractory B-Cell NHL
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
No filings found
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Registration Statement for Depositary Shares, Issued upon Effectiveness
Submission Upload
Correspondence